Exelixis’ (EXEL) Outperform Rating Reaffirmed at William Blair

William Blair reiterated their outperform rating on shares of Exelixis (NASDAQ:EXEL) in a research report sent to investors on Monday morning.

EXEL has been the topic of a number of other research reports. Zacks Investment Research upgraded shares of Exelixis from a hold rating to a strong-buy rating and set a $35.00 target price on the stock in a research report on Tuesday, January 2nd. Royal Bank of Canada raised their target price on shares of Exelixis from $33.00 to $39.00 and gave the company an outperform rating in a research report on Tuesday, October 17th. BidaskClub upgraded shares of Exelixis from a hold rating to a buy rating in a report on Thursday, January 25th. TheStreet upgraded shares of Exelixis from a c+ rating to a b- rating in a report on Wednesday, October 18th. Finally, Oppenheimer reiterated a hold rating on shares of Exelixis in a report on Tuesday, December 19th. Six research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of Buy and an average target price of $32.13.

Shares of Exelixis (NASDAQ:EXEL) opened at $29.05 on Monday. Exelixis has a 52-week low of $18.03 and a 52-week high of $32.50. The firm has a market cap of $8,346.02, a P/E ratio of 59.29, a price-to-earnings-growth ratio of 0.79 and a beta of 1.84.

In other news, Director Alan M. Garber sold 15,000 shares of Exelixis stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $30.30, for a total transaction of $454,500.00. Following the transaction, the director now owns 64,829 shares in the company, valued at $1,964,318.70. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 5.10% of the stock is currently owned by insiders.

Several large investors have recently modified their holdings of EXEL. Dimensional Fund Advisors LP lifted its holdings in shares of Exelixis by 4.8% during the second quarter. Dimensional Fund Advisors LP now owns 620,096 shares of the biotechnology company’s stock worth $15,273,000 after purchasing an additional 28,195 shares during the period. Stifel Financial Corp lifted its holdings in Exelixis by 8.5% in the second quarter. Stifel Financial Corp now owns 70,965 shares of the biotechnology company’s stock valued at $1,745,000 after buying an additional 5,584 shares during the period. QS Investors LLC lifted its holdings in Exelixis by 95.8% in the second quarter. QS Investors LLC now owns 15,540 shares of the biotechnology company’s stock valued at $383,000 after buying an additional 7,602 shares during the period. Employees Retirement System of Texas acquired a new position in Exelixis in the second quarter valued at $813,000. Finally, AHL Partners LLP acquired a new position in Exelixis in the second quarter valued at $757,000. Institutional investors own 81.43% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/13/exelixis-exel-outperform-rating-reaffirmed-at-william-blair.html.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Analyst Recommendations for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply